Marc Cluzel M.D., Ph.D. got his degrees from the University of Montpellier, in France. He started as Assistant Professor at Montpellier Hospital then continued to become visiting Assistant Professor for 3 years at Johns Hopkins University before moving to Guy’s Hospital London as Research Associate in 1990. In 1991 he joined Sanofi as a clinical pharmacologist where he moved up to become Head of Sanofi R&D in January 2007. From 1996 to 2006 Marc chaired the development operational committee. He actively participated in the life management of Plavix, Aprovel and Taxotere and registration of Fasturtec, Eloxatin, Arixtra, Uro-Xatral, Ambien CR, Multaq and Jevtana, in the US. He initiated the research collaboration with Regeneron. In January 2011 he founded C&F consulting. He is the Chairman of Morphosys AG, being a board member of since May 2012. He is a board member at Griffon Pharmaceuticals Inc.. Marc advises Moleac on various issues, including R & D and Clinical Research.